Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedMajor update: page now includes a government funding lapse notice and confirms the NIH Clinical Center is open, with status sources listed, and a version upgrade to v3.2.0.SummaryDifference8%
- Check24 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.2%
- Check38 days agoChange DetectedRevision updated to v3.0.2; Back to Top element removed. Core content and key data remain unchanged.SummaryDifference0.5%
- Check45 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.5%
- Check52 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries. These changes enhance the clarity and relevance of the page's content.SummaryDifference76%
- Check67 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.